Search

Your search keyword '"De Propris, M"' showing total 92 results
Start Over Author "De Propris, M"
92 results on '"De Propris, M"'

2. Early clearance of hairy cell leukaemia in the bone marrow after first‐line treatment with cladribine predicts a favourable outcome.

Author

Ligia, S., Passucci, M., Assanto, G. M., D'Elia, G. M., Annechini, G., De Propris, M. S., Martelli, M., Del Giudice, I., Tiacci, E., and Pulsoni, A.

Subjects
HAIRY cell leukemia, BONE marrow cells, BONE marrow, PROGRESSION-free survival
Abstract

Summary: First‐line purine nucleoside analogues (PNAs) in hairy cell leukaemia (HCL) allow deep and long‐lasting responses. We retrospectively analysed 53 HCL patients treated frontline with cladribine and assessed for response at 2 and 6 months after treatment to evaluate the kinetics of response. The estimated median progression‐free survival was significantly different according to the degree of residual HCL infiltrate detected by immunohistochemistry at the bone marrow biopsy at 2 months (≤5% vs. >5%, 247 vs. 132 months, respectively, p = 0.033), but not at 6 months (p = 0.79). Our data suggest a favourable prognostic impact of early marrow HCL clearance in patients treated with cladribine. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. S113: NATIONAL PEGASPARGASE-MODIFIED RISK-ORIENTED PROGRAM FOR PHILADELPHIA-NEGATIVE ADULT ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA (PH− ALL/LL). GIMEMA LAL 1913 FINAL RESULTS.

Author

Bassan, R., primary, Chiaretti, S., additional, Della Starza, I., additional, Spinelli, O., additional, Santoro, A., additional, Elia, L., additional, De Propris, M. S., additional, Scattolin, A. M., additional, Paoloni, F., additional, Messina, M., additional, Audisio, E., additional, Marbello, L., additional, Borlenghi, E., additional, Zappasodi, P., additional, Vetro, C., additional, Martinelli, G., additional, Mattei, D., additional, Fracchiolla, N., additional, Bocchia, M., additional, De Fabritiis, P., additional, Bonifacio, M., additional, Candoni, A., additional, Cassibba, V., additional, Di Bartolomeo, P., additional, Latte, G., additional, Trappolini, S., additional, Guarini, A., additional, Vitale, A., additional, Fazi, P., additional, Vignetti, M., additional, Rambaldi, A., additional, and Foà, R., additional

Published
2022
Full Text
View/download PDF

5. P353: FORTY MONTHS UPDATE OF THE GIMEMA LAL2116 (D-ALBA) PROTOCOL AND ANCILLARY LAL2217 STUDY FOR NEWLY DIAGNOSED ADULT PH+ ALL

Author

Chiaretti, S., primary, Bassan, R., additional, Vitale, A., additional, Elia, L., additional, Piciocchi, A., additional, Viero, P., additional, Ferrara, F., additional, Lunghi, M., additional, Fabbiano, F., additional, Bonifacio, M., additional, Fracchiolla, N., additional, Di Bartolomeo, P., additional, Fazi, P., additional, De Propris, M. S., additional, Vignetti, M., additional, Guarini, A., additional, Rambaldi, A., additional, and Foà, R., additional

Published
2022
Full Text
View/download PDF

6. P861: SIALOFUCOSYLATED STRUCTURES ENABLE PLATELET BINDING TO MYELOMA CELLS CONFERRING PROTECTION FROM NK-MEDIATED CYTOTOXICITY

Author

Natoni, A., primary, Cerreto, M., additional, De Propris, M. S., additional, Petrucci, M. T., additional, Del Giudice, I., additional, Intoppa, S., additional, Milani, M. L., additional, Kirkham-McCarthy, L., additional, Henderson, R., additional, Swan, D., additional, O’Dwyer, M., additional, Guarini, A., additional, and Foà, R., additional

Published
2022
Full Text
View/download PDF

7. Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia

Author

Moia, R., Dondolin, R., De Propris, M. S., Talotta, D., Mouhssine, S., Perutelli, F., Reda, G., Mattiello, V., Rigolin, G. M., Motta, M., Olivieri, J., Fanin, R., Perbellini, O., Ferrarini, I., Mauro, F. R., Del Giudice, I., Laurenti, Luca, Tomasso, Annamaria, Gentile, M., Frustaci, A. M., Tedeschi, Alessandra, Gozzetti, A., Stelitano, C., Visco, C., Moreno, C., Forconi, F., Marasca, R., Coscia, M., Rossi, Dario, Foa, Robin, Gaidano, G., Laurenti L. (ORCID:0000-0002-8327-1396), Tomasso A., Tedeschi A., Rossi D., Foa R., Moia, R., Dondolin, R., De Propris, M. S., Talotta, D., Mouhssine, S., Perutelli, F., Reda, G., Mattiello, V., Rigolin, G. M., Motta, M., Olivieri, J., Fanin, R., Perbellini, O., Ferrarini, I., Mauro, F. R., Del Giudice, I., Laurenti, Luca, Tomasso, Annamaria, Gentile, M., Frustaci, A. M., Tedeschi, Alessandra, Gozzetti, A., Stelitano, C., Visco, C., Moreno, C., Forconi, F., Marasca, R., Coscia, M., Rossi, Dario, Foa, Robin, Gaidano, G., Laurenti L. (ORCID:0000-0002-8327-1396), Tomasso A., Tedeschi A., Rossi D., and Foa R.

Abstract

NA

Published
2022

8. Efficacy of imatinib and chemotherapy in a pediatric patient with Philadelphia-like acute lymphoblastic leukemia with Ebf1-Pdgfrb fusion transcript

Author

Fazio, F, Barberi, W, Cazzaniga, G, Fazio, G, Messina, M, Della Starza, I, De Propris, M, Mancini, F, Mohamed, S, Del Giudice, I, Chiaretti, S, Moleti, M, Guarini, A, Foa, R, Testi, A, Fazio F., Barberi W., Cazzaniga G., Fazio G., Messina M., Della Starza I., De Propris M. S., Mancini F., Mohamed S., Del Giudice I., Chiaretti S., Moleti M. L., Guarini A., Foa R., Testi A. M., Fazio, F, Barberi, W, Cazzaniga, G, Fazio, G, Messina, M, Della Starza, I, De Propris, M, Mancini, F, Mohamed, S, Del Giudice, I, Chiaretti, S, Moleti, M, Guarini, A, Foa, R, Testi, A, Fazio F., Barberi W., Cazzaniga G., Fazio G., Messina M., Della Starza I., De Propris M. S., Mancini F., Mohamed S., Del Giudice I., Chiaretti S., Moleti M. L., Guarini A., Foa R., and Testi A. M.

Published
2020

15. Spontaneous Clinical Regression In Chronic Lymphocytic Leukemia : Clinical And Biologic Features Of 9 Cases From The ERIC Registry

Author

Del Giudice, I., Visentin, A., Trentin, L., Flogegard, M., Cavalloni, C., Orlandi, E., Mattsson, Mattias, Raponi, S., Ilari, C., Cafforio, L., De Propris, M. S., Della Starza, I., Peragine, N., Mariglia, P., Semenzato, G., Guarini, A., Montserrat, E., Foa, R., Del Giudice, I., Visentin, A., Trentin, L., Flogegard, M., Cavalloni, C., Orlandi, E., Mattsson, Mattias, Raponi, S., Ilari, C., Cafforio, L., De Propris, M. S., Della Starza, I., Peragine, N., Mariglia, P., Semenzato, G., Guarini, A., Montserrat, E., and Foa, R.

Published
2017

16. Very late relapse in a patient with acute promyelocytic leukemia (APL) rescued with a chemotherapy-free protocol

Author

Testi, A. M., Moleti, M. L., Canichella, M., Mohamed, S., Diverio, D., de Propris, M. S., Locatelli, Franco, Lo Coco, F., Foa, R., Locatelli F. (ORCID:0000-0002-7976-3654), Testi, A. M., Moleti, M. L., Canichella, M., Mohamed, S., Diverio, D., de Propris, M. S., Locatelli, Franco, Lo Coco, F., Foa, R., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

NO ABSTRACT

Published
2017

17. RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications

Author

Gianfelici, V., primary, Chiaretti, S., additional, Demeyer, S., additional, Di Giacomo, F., additional, Messina, M., additional, La Starza, R., additional, Peragine, N., additional, Paoloni, F., additional, Geerdens, E., additional, Pierini, V., additional, Elia, L., additional, Mancini, M., additional, De Propris, M. S., additional, Apicella, V., additional, Gaidano, G., additional, Testi, A. M., additional, Vitale, A., additional, Vignetti, M., additional, Mecucci, C., additional, Guarini, A., additional, Cools, J., additional, and Foa, R., additional

Published
2016
Full Text
View/download PDF

18. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients

Author

Foà, R, Del Giudice, I, Cuneo, Antonio, Del Poeta, G, Ciolli, S, Di Raimondo, F, Lauria, F, Cencini, E, Rigolin, Gian Matteo, Cortelezzi, A, Nobile, F, Callea, V, Brugiatelli, M, Massaia, M, Molica, S, Trentin, L, Rizzi, R, Specchia, G, Di Serio, F, Orsucci, L, Ambrosetti, A, Montillo, M, Luigi Zinzani, P, Ferrara, F, Morabito, F, Angela Mura, M, Soriani, S, Peragine, N, Tavolaro, S, Bonina, S, Marinelli, M, Stefania De Propris, M, Della Starza, I, Piciocchi, A, Alietti, A, Runggaldier, Ej, Gamba, E, Romana Mauro, F, Chiaretti, S, Guarini, A., R. Foà, I. D. Giudice, A. Cuneo, G. D. Poeta, S. Ciolli, F. D. Raimondo, F. Lauria, E. Cencini, G. M. Rigolin, A. Cortelezzi, F. Nobile, V. Callea, M. Brugiatelli, M. Massaia, S. Molica, L. Trentin, R. Rizzi, G. Specchia, F. D. Serio, L. Orsucci, A. Ambrosetti, M. Montillo, P. L. Zinzani, F. Ferrara, F. Morabito, M. A. Mura, S. Soriani, N. Peragine, S. Tavolaro, S. Bonina, M. Marinelli, M. S. De, I. D. Starza, A. Piciocchi, A. Alietti, E. J. Runggaldier, E. Gamba, F. R. Mauro, S. Chiaretti, and A. Guarini

Subjects
Male, Murine-Derived, drug therapy/pathology, Male, Survival Analysis, Treatment Outcome, Antibodies, Disease-Free Survival, Drug Administration Schedule, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Combined Chemotherapy Protocols, Monoclonal, 80 and over, 80 and over, Antibodie, Humans, therapeutic use, Chlorambucil, Chronic, Aged, Aged, 80 and over, Aged, Aged, Leukemia, Chlorambucil, Female, Induction Chemotherapy, Leukemia, Lymphocytic, Chronic, B-Cell, Rituximab, Survival Analysis, Treatment Outcome, Hematology, B-Cell, Lymphocytic, CLL, chlorambucil, administration /&/ dosage, Antineoplastic Combined Chemotherapy Protocol, administration /&/ dosage, Disease-Free Survival, Drug Administration Schedule, Female, Humans, Induction Chemotherapy, Leukemia, Settore MED/15 - Malattie del Sangue
Abstract

In a phase II trial, we evaluated chlorambucil and rituximab (CLB-R) as first-line induction treatment with or without R as maintenance for elderly chronic lymphocytic leukemia (CLL) patients. Treatment consisted of eight 28-day cycles of CLB (8 mg/m(2) /day, days 1-7) and R (day 1 of cycle 3, 375 mg/m(2) ; cycles 4-8, 500 mg/m(2) ). Responders were randomized to 12 8-week doses of R (375 mg/m(2) ) or observation. As per intention-to-treat analysis, 82.4\% (95\% CI, 74.25-90.46\%) of 85 patients achieved an overall response (OR), 16.5\% a complete response (CR), 2.4\% a CR with incomplete bone marrow recovery. The OR was similar across Binet stages (A 86.4\%, B 81.6\%, and C 78.6\%) and age categories (60-64 years, 92.3\%; 65-69, 85.2\%; 70-74, 75.0\%; ≥75, 81.0\%). CLB-R was well tolerated. After a median follow-up of 34.2 months, the median progression-free survival (PFS) was 34.7 months (95\% CI, 33.1-39.5). TP53 abnormalities, complex karyotype, and low CD20 gene expression predicted lack of response; SF3B1 mutation and BIRC3 disruption low CR rates. IGHV mutations significantly predicted PFS. R maintenance tended towards a better PFS than observation and was safe and most beneficial for patients in partial response and for unmutated IGHV cases. CLB-R represents a promising option for elderly CLL patients.

Published
2014

22. Efficacy and Safety of a First-Line Combined Therapeutic Approach for Young CLL Patients Stratified According to the Biological Prognostic Features: First Analysis of the GIMEMA Multicenter LLC0405 Study

Author

Mauro, F. R., Cortelezzi, A., Molica, S., Laurenti, L., Liso, V., Rizzi, R., Carella, A. M., DI RAIMONDO, Francesco, Marasca, R., Fioritoni, G., Brugiatelli, M., Musolino, C., Lauria, F., Buccisano, F., Zaja, F., Callea, V., Morabito, F., Massaia, M., Gentile, G., DEL GIUDICE, I., DE PROPRIS, M. S., DELLA STARZA, I., Marinelli, M., Santangelo, S., Nanni, M., Vignetti, M., Graziosi, A., Specchia, G., Cuneo, A., Guarini, A., Blood, AND R. FOÀ ., and Vol, P.

Published
2008

32. Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile

Author

Mauro, Fr, Molica, S, Laurenti, Luca, Cortelezzi, A, Carella, Am, Zaja, F, Chiarenza, A, Angrilli, F, Nobile, F, Marasca, R, Musolino, C, Brugiatelli, M, Piciocchi, A, Vignetti, M, Fazi, P, Gentile, G, De Propris, M, Starza, Id, Marinelli, M, Chiaretti, S, Del Giudice, I, Nanni, M, Albano, F, Cuneo, A, Guarini, A, Foà, R., Laurenti, Luca (ORCID:0000-0002-8327-1396), Mauro, Fr, Molica, S, Laurenti, Luca, Cortelezzi, A, Carella, Am, Zaja, F, Chiarenza, A, Angrilli, F, Nobile, F, Marasca, R, Musolino, C, Brugiatelli, M, Piciocchi, A, Vignetti, M, Fazi, P, Gentile, G, De Propris, M, Starza, Id, Marinelli, M, Chiaretti, S, Del Giudice, I, Nanni, M, Albano, F, Cuneo, A, Guarini, A, Foà, R., and Laurenti, Luca (ORCID:0000-0002-8327-1396)

Abstract

In 45, ≤60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab(®)) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic features.

Published
2014

33. Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells

Author

Torelli, G. F., primary, Peragine, N., additional, Raponi, S., additional, Pagliara, D., additional, De Propris, M. S., additional, Vitale, A., additional, Bertaina, A., additional, Barberi, W., additional, Moretta, L., additional, Basso, G., additional, Santoni, A., additional, Guarini, A., additional, Locatelli, F., additional, and Foa, R., additional

Published
2014
Full Text
View/download PDF

34. Early detection of meningeal localization in acute promyelocytic leukaemia patients with high presenting leucocyte count

Author

Breccia, M, Carmosino, I, Diverio, D, De Santis, S, De Propris, M, Romano, A, Petti, M, Mandelli, F, and LO COCO, F

Subjects
Promyelocytic, Adult, Male, Leukemia, Tretinoin, Acute, Middle Aged, Antineoplastic Combined Chemotherapy Protocols, Central Nervous System Diseases, Female, Humans, Idarubicin, Leukemia, Promyelocytic, Acute, Leukemic Infiltration, Leukocyte Count, Meninges, Recurrence, Spinal Puncture, Settore MED/15 - Malattie del Sangue
Abstract

Extramedullary relapse occurs infrequently in acute promyelocytic leukaemia (APL) but has been increasingly reported after the advent of all-trans retinoic acid (ATRA) treatment, probably as a consequence of improved patient survival. We describe our single centre experience of six APL patients who had disease localization in the central nervous system (CNS). In three patients, clinical symptoms (headache and/or nausea) that presented during follow-up led to the performance of a lumbar puncture and detection of overt CNS infiltration. Two of these patients had simultaneous haematological relapse and one was in molecular remission when CNS leukaemia was documented. One patient with no local symptoms showed CNS infiltration at the time of molecular relapse. Following the introduction of routine lumbar puncture, carried out after front-line induction in all newly diagnosed patients with white blood cell count (WBC) greater than 10 x 109/l, two additional patients in molecular remission with no local symptoms were found to have initial APL localization in the CNS. Presenting features included in 6/6 patients an elevated WBC count (10 x 109/l) and a predominance of the PML/RAR bcr3 type (5/6 patients) and of microgranular morphology (5/6 patients). Our findings highlight the importance of carrying out lumbar puncture in APL patients presenting with high-risk features.

Published
2003

37. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

Author

Foà, R, Vitale, A, Vignetti, M, Meloni, G, Guarini, A, De Propris, M, Elia, L, Paoloni, F, Fazi, P, Cimino, G, Nobile, F, Ferrara, F, Castagnola, C, Sica, Simona, Leoni, P, Zuffa, E, Fozza, C, Luppi, M, Candoni, A, Iacobucci, I, Soverini, S, Mandelli, F, Martinelli, G, Baccarani, M., Sica, Simona (ORCID:0000-0003-2426-3465), Foà, R, Vitale, A, Vignetti, M, Meloni, G, Guarini, A, De Propris, M, Elia, L, Paoloni, F, Fazi, P, Cimino, G, Nobile, F, Ferrara, F, Castagnola, C, Sica, Simona, Leoni, P, Zuffa, E, Fozza, C, Luppi, M, Candoni, A, Iacobucci, I, Soverini, S, Mandelli, F, Martinelli, G, Baccarani, M., and Sica, Simona (ORCID:0000-0003-2426-3465)

Abstract

Dasatinib is a potent BCR-ABL inhibitor effective in chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia (ALL) resistant/intolerant to imatinib. In the GIMEMA LAL1205 protocol, patients with newly diagnosed Ph(+) ALL older than 18 years (with no upper age limit) received dasatinib induction therapy for 84 days combined with steroids for the first 32 days and intrathecal chemotherapy. Postremission therapy was free. Fifty-three patients were evaluable (median age, 53.6 years). All patients achieved a complete hematologic remission (CHR), 49 (92.5%) at day 22. At this time point, 10 patients achieved a BCR-ABL reduction to < 10(-3). At 20 months, the overall survival was 69.2% and disease-free survival was 51.1%. A significant difference in DFS was observed between patients who showed at day 22 a decrease in BCR-ABL levels to < 10(-3) compared with patients who never reached these levels during induction. In multivariate analysis, BCR-ABL levels of < 10(-3) at day 85 correlated with disease-free survival. No deaths or relapses occurred during induction. Twenty-three patients relapsed after completing induction. A T315I mutation was detected in 12 of 17 relapsed cases. Treatment was well tolerated; only 4 patients discontinued therapy during the last phase of the induction when already in CHR. In adult Ph(+) ALL, induction treatment with dasatinib plus steroids is associated with a CHR in virtually all patients, irrespective of age, good compliance, no deaths, and a very rapid debulking of the neoplastic clone.

Published
2011

39. ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression

Author

Guarini, A., primary, Marinelli, M., additional, Tavolaro, S., additional, Bellacchio, E., additional, Magliozzi, M., additional, Chiaretti, S., additional, De Propris, M. S., additional, Peragine, N., additional, Santangelo, S., additional, Paoloni, F., additional, Nanni, M., additional, Del Giudice, I., additional, Mauro, F. R., additional, Torrente, I., additional, and Foa, R., additional

Published
2011
Full Text
View/download PDF

41. White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia

Author

Del Giudice, I., primary, Mauro, F. R., additional, De Propris, M. S., additional, Santangelo, S., additional, Marinelli, M., additional, Peragine, N., additional, Di Maio, V., additional, Nanni, M., additional, Barzotti, R., additional, Mancini, F., additional, Armiento, D., additional, Paoloni, F., additional, Guarini, A., additional, and Foa, R., additional

Published
2010
Full Text
View/download PDF

43. Clinical and biological features of acute promyelocytic leukemia patients developing retinoic acid syndrome during induction treatment with all-trans retinoic acid and idarubicin

Author

Breccia, M., primary, Latagliata, R., additional, Carmosino, I., additional, Cannella, L., additional, Diverio, D., additional, Guarini, A., additional, De Propris, M. S., additional, Petti, M. C., additional, Avvisati, G., additional, Cimino, G., additional, Mandelli, F., additional, and Lo-Coco, F., additional

Published
2008
Full Text
View/download PDF

48. Complete remission through blast cell differentiation inPLZF/RARα-positive acute promyelocytic leukemia: in vitro and in vivo studies

Author

Petti, Maria C., primary, Fazi, Francesco, additional, Gentile, Massimo, additional, Diverio, Daniela, additional, De Fabritiis, Paolo, additional, De Propris, M. Stefania, additional, Fiorini, Roberto, additional, Spiriti, Maria A. Aloe, additional, Padula, Fabrizio, additional, Pelicci, Pier Giuseppe, additional, Nervi, Clara, additional, and Lo Coco, Francesco, additional

Published
2002
Full Text
View/download PDF

49. Monitoring of CD34+ cells during leukapheresis allows a single, successful collection of hemopoietic progenitors in patients with low numbers of circulating stem cells.

Author

de Fabritiis, P, Gonzalez, M, Meloni, G, De Propris, M S, Bellucci, R, Cordone, I, Gozzer, M, Leone, G, and Mandelli, F

Subjects
HEMATOLOGICAL oncology, GRANULOCYTE-colony stimulating factor, LEUKAPHERESIS, AUTOTRANSPLANTATION, STEM cells
Abstract

We have studied a total of 188 patients with hematological malignancies, submitted to mobilization therapy with G-CSF associated or not with chemotherapy in order to: (1) establish the lower limit of circulating progenitor cells that allows the collection of 2 × 106CD34+ cells/kg by a single leukapheresis, utilizing the instrument set on standard parameters; (2) evaluate whether the number and quality of CD34+ cells collected remain stable during leukapheresis; and (3) collect a sufficient number of circulating CD34+ cells by a single procedure in patients in whom such an approach would have been insufficient to reach the target with the instrument set on standard parameters. The retrospective analysis conducted in 85 patients showed that 19 circulating CD34+ cells/μl represented the cut-off number capable of discriminating between patients who will require one or more apheresis to collect 2 × 106 CD34+ cells/kg. The validity of this value was prospectively confirmed in 70 subsequent patients. Based on in vitroresults that showed the stability in the number of CD34+ cells, the proportion of different CD34+ cell subpopulations and the clonogenic capacity of the stem cell compartment during leukapheresis both in the blood of the patients and in samples taken directly from the instrument, we have adapted the blood volume to be processed in 33 patients with <19 pb cd34+ cells/μl. Stem cell collection was monitored during the leukapheresis and the procedure was prolonged for a time period estimated to be sufficient to reach the target number of CD34+ cells with a single procedure. The median increment of the total blood volume processed, calculated from the volume set automatically by the instrument was 25.2%, with a median of 3.3-fold total blood volume processed. In all cases, a sufficient CD34+ cell collection was... [ABSTRACT FROM AUTHOR]

Published
1999
Full Text
View/download PDF

50. Modulation of VLA-4 and L-selectin expression on normal CD34+ cells during mobilization with G-CSF.

Author

Bellucci, R, De Propris, M S, Buccisano, F, Lisci, A, Leone, G, Tabilio, A, and de Fabritiis, P

Subjects
*CD antigens, *GRANULOCYTE-colony stimulating factor, *BLOOD cells
Abstract

We have evaluated the immunophenotype, functional activity and clonogenic potential of CD34+ cells from peripheral blood (PB) of normal donors before and after 4 and 6 days of G-CSF administration. The percentage and absolute number of CD34+ cells significantly increased at days 4 and 6 of G-CSF administration, compared to the steady-state level (P < 0.0001). two-colour fluorescence analysis showed, at days 4 and 6, a lower proportion of cd34+/c-kit+ compared to the steady-state level (P < 0.0001), but a similar expression of cd13, cd33, cd38, hla-dr and thy-1 antigens on cd34+ cells. The expression of adhesion molecules on CD34+ cells revealed a significant reduction of CD11a (P = 0.009), CD18, CD49d and CD62L (P < 0.0001) at days 4 and 6, compared to the baseline level. three-colour staining showed a reduction of the more immature compartment (34+/DR-/13-) and an increase of the more differentiated compartment (34+/DR+/13+). Downregulation of VLA-4 during mobilisation was seen almost exclusively on more committed cells (34+/13+); downregulation of CD62L, on the contrary, was observed on both early progenitors (34+/13-) and more committed cells (34+/13+). The expression of 34+/VLA-4+ decreased on both c-kit+ and c-kit- cells, while the expression of 34+/62L+ decreased on the c-kit+ cells only. In vivo administration of G-CSF reduced the adherence capacity of CD34+ cells to normal BM stroma; in vitro incubation with SCF or IL-3 enhanced the expression of CD49d on CD34+ cells, while GM-CSF reduced the expression of CD62L. SCF was the only cytokine able to induce a significant increase of CD34+ cell adherence to preformed stroma. Pre-incubation with the... [ABSTRACT FROM AUTHOR]

Published
1999
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results